Accumulated evidence suggests that a lot of radiosensitizing compounds function as anti-cancer agents via the induction of the G2/M cell-cycle arrest through downregulating Cyclin B and CDK1 expression (39, 40), and fenofibrate was reported to induce G2/M cell-cycle arrest through reducing the activity of the CDK1/Cyclin B1 kinase complex, thereby increasing the radiosensitivity (41).Taken together, it is therefore considered that ANXA2 is involved in the mediation of the G2/M cell-cycle arrest, thereby affecting the efficacy of radiotherapy. Here, CDK1 is linked to cancer.